Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease

Published:2010-07 Issue:7 Volume:16 Page:1209-1218
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Sands Bruce E.,Jacobson Eric W.,Sylwestrowicz Thomas,Younes Ziad,Dryden Gerald,Fedorak Richard,Greenbloom Susan

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference24 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease

2. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

3. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities

4. Interleukin-12 and the regulation of innate resistance and adaptive immunity

5. TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases;Proceedings of the National Academy of Sciences;2024-08-16

2. PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2;2024-04-17

3. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial;Brain;2024-04-12

4. Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis;Inflammatory Bowel Diseases;2024-03-01

5. Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice;Antimicrobial Agents and Chemotherapy;2024-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3